Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 12—December 2014
Research

Variably Protease-Sensitive Prionopathy, a Unique Prion Variant with Inefficient Transmission Properties

Abigail B. Diack1, Diane Ritchie1, Alexander H. Peden, Deborah Brown, Aileen Boyle, Laura Morabito, David Maclennan, Paul Burgoyne, Casper Jansen, Richard S. Knight, Pedro Piccardo, James W. Ironside1, and Jean C. Manson1Comments to Author 
Author affiliations: The Roslin Institute, University of Edinburgh, Easter Bush, Scotland, UK (A.B. Diack, D. Brown, A, Boyle, L. Morabito, D. Maclennan, P. Burgoyne, J.C. Manson); School of Clinical Sciences, University of Edinburgh, Edinburgh, Scotland, UK (D.L. Ritchie, A.H. Peden, R.S. Knight, J.W. Ironside); Food and Drug Administration, Rockville, Maryland, USA (P. Piccardo); University Medical Centre Utrecht, Utrecht, the Netherlands (C. Jansen)

Main Article

Table 1

Characteristics of patients with variably protease-sensitive prionopathy whose brain samples were selected for transmission studies*

Patient, sex
Age at death, y
Disease duration, mo
Clinical signs and symptoms
Neuropathologic features
PrPres type
NL-VV, M†
57
20
Progressive dementia, spastic paraplegia, sensorimotor polyneuropathy
Mild to moderate spongiform change in basal ganglia, and cerebral and cerebellar cortices. Coarse granular deposits of PrP in cerebral cortex, basal ganglia, and thalamus. PrP microplaques present within molecular layer of cerebellar cortex
Faint ladder-like appearance of protease-resistant fragments with a prominent low–molecular weight fragment
UK-VV, F‡
59
42
Progressive dementia, emotional and obsessive behavior (early), very occasional myoclonus (late)
Mild to moderate spongiform change in basal ganglia, thalamus, and cerebral and cerebellar cortices. Widespread granular accumulations of PrP in all brain regions. PrP microplaques present within molecular layer of cerebellar cortex
Faint, ladder-like appearance of protease-resistant fragments with a prominent low–molecular weight fragment
UK-MV, M§ 76 12 Forgetfulness, visuospatial perceptual problems, difficulties walking, action tremor, akinetic mutism Spongiform change most prominent in the frontal cortex. PrP microplaques, synaptic and granular accumulations of PrP restricted to cerebral cortex, basal ganglia, and thalamus. Diffuse Lewy body and tau pathology observed, with
amyloid-β plaques and a widespread amyloid angiopathy Faint ladder-like appearance of protease-resistant fragments including a low–molecular weight fragment

*PrP, prion protein; PrPres, protease-resistant isoform of the disease-specific PrP.
†NL-VV, patient from the Netherlands who was homozygous for valine at codon 129 of the PrP gene (PRNP). Case report, Jansen et al. (6).
‡UK-VV, patient from the United Kingdom who was homozygous for valine at PRNP codon 129. Case report, Head et al. (5).
§UK-MV, patient from the United Kingdom who was heterozygous for methionine/valine at PRNP codon 129. Case report, Head et al. (17).

Main Article

References
  1. Parchi  P, Saverioni  D. Molecular pathology, classification, and diagnosis of sporadic human prion disease variants. Folia Neuropathol. 2012;50:2045 .PubMedGoogle Scholar
  2. Jansen  C, Parchi  P, Capellari  S, Ibrahim-Verbaas  CA, Schuur  M, Strammiello  R, Human prion diseases in the Netherlands (1998–2009): clinical, genetic and molecular aspects. PLoS ONE. 2012;7:e36333. DOIPubMedGoogle Scholar
  3. Bishop  MT, Will  RG, Manson  JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci U S A. 2010;107:1200510. DOIPubMedGoogle Scholar
  4. Gambetti  P, Dong  Z, Yuan  J, Xiao  X, Zheng  M, Alshekhlee  A, A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol. 2008;63:697708. DOIPubMedGoogle Scholar
  5. Head  MW, Knight  R, Zeidler  M, Yull  H, Barlow  A, Ironside  JW. A case of protease sensitive prionopathy in a patient in the UK. Neuropathol Appl Neurobiol. 2009;35:62832. DOIPubMedGoogle Scholar
  6. Jansen  C, Head  MW, van Gool  WA, Baas  F, Yull  H, Ironside  JW, The first case of protease-sensitive prionopathy (PSPr) in the Netherlands: a patient with an unusual GSS-like clinical phenotype. J Neurol Neurosurg Psychiatry. 2010;81:10525. DOIPubMedGoogle Scholar
  7. Rodríguez-Martínez  AB, Garrido  JM, Zarranz  JJ, Arteagoitia  JM, de Pancorbo  MM, Atares  B, A novel form of human disease with a protease-sensitive prion protein and heterozygosity methionine/valine at codon 129: case report. BMC Neurol. 2010;10:99. DOIPubMedGoogle Scholar
  8. Parchi  P, Giese  A, Capellari  S, Brown  P, Schulz-Schaeffer  W, Windl  O, Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46:22433. DOIPubMedGoogle Scholar
  9. Nurmi  MH, Bishop  M, Strain  L, Brett  F, McGuigan  C, Hutchison  M, The normal population distribution of PRNP codon 129 polymorphism. Acta Neurol Scand. 2003;108:3748. DOIPubMedGoogle Scholar
  10. Zou  WQ, Puoti  G, Xiao  X, Yuan  J, Qing  L, Cali  I, Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol. 2010;68:16272. DOIPubMedGoogle Scholar
  11. Wroe  SJ, Pal  S, Siddique  D, Hyare  H, Macfarlane  R, Joiner  S, Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet. 2006;368:20617. DOIPubMedGoogle Scholar
  12. Peden  AH, Head  MW, Ritchie  DL, Bell  JE, Ironside  JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:5279. DOIPubMedGoogle Scholar
  13. Llewelyn  CA, Hewitt  PE, Knight  RSG, Amar  K, Cousens  S, Mackenzie  J, Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:41721. DOIPubMedGoogle Scholar
  14. Bishop  MT, Diack  AB, Ritchie  DL, Ironside  JW, Will  RG, Manson  JC. Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease. Brain. 2013;136:113945. DOIPubMedGoogle Scholar
  15. Bishop  MT, Hart  P, Aitchison  L, Baybutt  HN, Plinston  C, Thomson  V, Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol. 2006;5:3938. DOIPubMedGoogle Scholar
  16. Bishop  MT, Ritchie  DL, Will  RG, Ironside  JW, Head  MW, Thomson  V, No major change in vCJD agent strain after secondary transmission via blood transfusion. PLoS ONE. 2008;3:e2878. DOIPubMedGoogle Scholar
  17. Head  MW, Lowrie  S, Chohan  G, Knight  R, Scoones  DJ, Ironside  JW. Variably protease-sensitive prionopathy in a PRNP codon 129 heterozygous UK patient with co-existing tau, α synuclein and Aβ pathology. Acta Neuropathol. 2010;120:8213. DOIPubMedGoogle Scholar
  18. Fraser  H, Dickinson  AG. The sequential development of the brain lesion of scrapie in three strains of mice. J Comp Pathol. 1968;78:30111. DOIPubMedGoogle Scholar
  19. Yull  HM, Ritchie  DL, Langeveld  JP, van Zijderveld  FG, Bruce  ME, Ironside  JW, Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. Am J Pathol. 2006;168:1517. DOIPubMedGoogle Scholar
  20. Kovács  GG, Head  MW, Hegyi  I, Bunn  TJ, Flicker  H, Hainfellner  JA, Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes. Brain Pathol. 2002;12:111. DOIPubMedGoogle Scholar
  21. Prusiner  SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:13644. DOIPubMedGoogle Scholar
  22. Jucker  M, Walker  LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:53240. DOIPubMedGoogle Scholar
  23. Scott  JR, Davies  D, Fraser  H. Scrapie in the central nervous system: neuroanatomical spread of infection and Sinc control of pathogenesis. J Gen Virol. 1992;73:163744. DOIPubMedGoogle Scholar
  24. Barron  RM, Campbell  SL, King  D, Bellon  A, Chapman  KE, Williamson  RA, High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo. J Biol Chem. 2007;282:3587886. DOIPubMedGoogle Scholar
  25. Piccardo  P, King  D, Telling  G, Manson  JC, Barron  RM. Dissociation of prion protein amyloid seeding from transmission of a spongiform encephalopathy. J Virol. 2013;87:1234956. DOIPubMedGoogle Scholar
  26. Baker  HF, Ridley  RM, Duchen  LW, Crow  TJ, Bruton  CJ. Experimental induction of β-amyloid plaques and cerebral angiopathy in primates. Ann N Y Acad Sci. 1993;695:22831. DOIPubMedGoogle Scholar
  27. Piccardo  P, Manson  JC, King  D, Ghetti  B, Barron  RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci U S A. 2007;104:47127. DOIPubMedGoogle Scholar
  28. Plinston  C, Hart  P, Chong  A, Hunter  N, Foster  J, Piccardo  P, Increased susceptibility of human-PrP transgenic mice to bovine spongiform encephalopathy infection following passage in sheep. J Virol. 2011;85:117481. DOIPubMedGoogle Scholar

Main Article

1These authors contributed equally to this article.

Page created: November 18, 2014
Page updated: November 18, 2014
Page reviewed: November 18, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external